There is one kit size for 100 tests and one for 500 tests.
The larger hospitals have automated PCR analysis lines. We have taken this into account in the development.
Since the typical automated liquid handling systems (ALH) are very flexible regarding the vials, the kit should be applicable on most common ALH or integrated automated PCR assay setups such as QiaSymphony and Hologic.
The test should be able to be performed with all RNA isolation kits. We tested the kit with the isolation kits from Qiagen and Sigma-Aldrich.
The test runs on common real-time cyclers. Only RNA isolation kits are required.
RT-PCR reaction tubes with caps or foils
DEPC H2O / Aqua dest. / WFI (Ampuwa®)
- Piston pipettes (0,5 – 1000 μl) and tips
No cooling is required for transport. Therefore, significantly lower logistics costs can be expected.
For permanent storage we recommend a control temperature of - 20 degrees Celsius.
There is no need for a software, the labs do an excel based data analysis based on CT values.
So far, we tested nasopharyngeal swabs at BAG and in customer labs.
Blood and stool samples have a higher risk of PCR failure due to "common inhibitors" and usually lower virus titres and are, therefore, not recommended.
The test is CE IVD certified.
We have an extensive stock. In addition, thanks to short lead times, we can also realize larger orders in about 3 to 4 weeks.
As an alternative to our real-time PCR test, you can use our SARS-CoV-2 antigen rapid test. By taking a nasal swab (which should always be prepared by qualified personnel), a result can be read quickly and easily on site within 15 minutes.
Important: Depending on the time of the swab, a negative result does not completely exclude an infection. However, a positive result indicates an infection and should be verified by PCR testing. As access control to vulnerable groups of people and in areas with many contact points, the rapid test is therefore an ideal indicator.
Currently, we have focused on the detection of COVID-19, as it is detectable immediately after infection. This allows us to very quickly localize infected persons as carriers of the virus. Antibodies are built at the earliest from the second week of infection. Therefore, these tests are not effective in the first, highly infectious phase of the disease.
However, we are working with partners on a rapid antibody test. This is intended to identify recovered patients reliably. The same applies to the estimated number of untested persons who have produced antibodies with only minor symptoms or without findings and are therefore immunized.